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cancer (-54%), CIN1 (-71%), CIN2/3 (-70%), genital warts among females (-75%) and 
males (-63%), and cervical cancer deaths (-52%). Routine vaccination also resulted in 
reduction of disease costs for cervical cancer (-24%), CIN1 (-42), CIN2/3 (-41%), genital 
warts in females (-52%) and males (-42%). The reduction in HPV6/11-related disease 
incidence and costs avoided occurred relatively soon after vaccination, especially 
CIN1 and genital warts. Considering the recommended threshold of 160,000 THB/
QALY, both routine and routine plus catch-up programs are cost-effective with dis-
counted incremental cost-effectiveness ratios (ICER) of 35,124 and 34,426 THB/QALY, 
respectively. The ICER increased by about 31% for both strategies when HPV6/11-
related effects were excluded. ConClusions: The school-based HPV vaccination 
program, using the quadrivalent HPV vaccine, is cost-effective, particularly when 
catch-up vaccination is incorporated. The results support decision-making process 
to include HPV vaccination in Thailand NIP.
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objeCtives: Cisplatin plus pemetrexed (Cis/Pem) is a more costly chemotherapy 
regimen than carboplatin plus paclitaxel (Carb/Pac), but with the reports about its 
higher efficacy and less toxicity. Thus, this study aimed to assess the cost-utility 
of these two chemotherapy regimens in advanced non-squamous non-small cell 
lung cancer (NSCLC) in Thailand. Methods: Economic study was conducted along 
a prospective cohort study in Maharaj Nakorn Chiang Mai hospital located in the 
north of Thailand. Patients aged 18 or above, diagnosed with non-squamous NSCLC 
with stage IIIB and IV, had performance status (ECOG) 0-1, and were treated either 
Cis/Pem or Carb/Pac was enrolled during January 2012 to June 2013. Direct and 
indirect costs were collected considering the societal perspective. Effectiveness was 
measured in terms on time days to disease progression. The incremental cost per 
quality-adjusted time to disease progression was calculated. A series of sensitiv-
ity analyses were also performed. Results: Of the total 54 patients, 36 received 
Carb/Pac and the remaining received Cis/Pem. Median time to disease progression 
was 119.94 days and 100.17 days for patients who received Cis/Pem and Carb/Pac 
respectively. Cis/Pem regimen had a higher total cost of 463,678 Bath per case while 
gained 15.95 quality adjusted-day to progression compared with Carb/Pac regimen. 
The resulted in 29,078.92 Baht per quality adjusted time day to progression per 
patient. ConClusions: Our findings suggested that Cis/Pem regimen gains slightly 
more effectiveness than Carb/Pac regimen with rising additional cost incurred. 
However, in cancer treatment, selection the appropriate treatment to individual 
patients might need to consider other issues such as quality of life. Beyond only 
health care resources.
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objeCtives: Abraxane® and Taxol® are both effective agents for the treatment of 
advanced stage breast cancer. However, each agent possesses unique drug delivery 
characteristics with the former not requiring premedication and having a consider-
ably shorter recommended infusion time (i.e. 30 min vs. 2 - 4 hours). To measure the 
overall efficiency and cost saving potential associated with Abraxane® relative to 
Taxol®, a time and motion study was undertaken in breast cancer patients treated 
in China. Methods: Baseline data collection included patient and disease charac-
teristics. Time and resource use data were then collected from breast patients being 
treated with Abraxane® (n= 12) or Taxol® (n= 15) in one of three cancer clinics located 
in Jiangsu, Shanghai and Beijing. Resource use and time impact on clinical staff 
were quantified using unit cost estimates. This included costs for drug preparation, 
administration, materials and supplies, premedication, patient chair time, labor 
costs and all acute adverse drug reactions. All costs were reported in $U.S. (1$U.S. = 
6.1 RMB). Results: Approximately 9 of 12 (75%) patients received Abraxane® as on 
a weekly schedule compared to 6 of 15 (40%) with Taxol®. There were 5 (33.3%) acute 
adverse drug reactions with Taxol®, 3 of which required a physician visit and the 
initiation of supportive interventions. In contrast, there was only one minor event 
with Abraxane® (8.3%), which was easily managed with a temporary stoppage of the 
infusion. From the time and motion study, the mean total time for Abraxane® and 
Taxol® delivery was 84 and 282 minutes (p < 0.001), with the associated costs being 
$59 and $254 respectively per dose (p < 0.001). ConClusions: To our knowledge, 
this is first such study in breast cancer patients undertaken in China. Abraxane® 
was associated with fewer acute adverse drug reactions and significant reductions 
in health care resources, physician/nurse time and overall drug delivery costs com-
pared to Taxol®.
CANCer – Patient-reported outcomes & Patient Preference studies
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objeCtives: The aim of the study was to explore knowledge on HPV, and to learn 
about women’s attitudes to vaccination in Hungary. Methods: A quantitative cross-
sectional study was performed among the mothers of girl students in a public edu-
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objeCtives: To evaluate the health and economic benefits of different screening 
and vaccination strategies against cervical cancer in the Philippines. Methods: A 
cost-utility analysis was conducted using an existing semi-Markov model to evalu-
ate different screening (i.e. Pap smear, visual acetic acid) and vaccination strategies 
against HPV infection implemented alone or as part of a combination strategy at 
different coverage scenarios. From a health system perspective, the researchers 
ran the model using country-specific epidemiologic, cost and clinical parameters. 
Sensitivity analysis was performed for vaccine efficacy, duration of protection and 
costs of vaccination, screening and treatment. Results: Across all coverage sce-
narios, VIA has been shown to be a dominant and cost-saving strategy with ICERs 
ranging from -Php 191,099 to Php 61,058.73 per QALY gained. Due to its high cost in 
the Philippines, Pap smear was found to be not cost-effective. At a cost of Php 2,400 
per vaccinated girl, vaccination was found to be cost-effective at a threshold of 1 
GDP per capita with the most favorable assumption of providing lifelong immunity 
against high-risk oncogenic HPV types 16/18. The highest incremental QALY gain 
was achieved with 80% coverage of the combined strategy of VIA at 35 to 45 years 
old done every five years following vaccination at 11 years of age with an ICER of 
Php 33,126. HPV vaccination becomes less cost-effective when vaccine protection 
lasts for less than 15 years. ConClusions: High VIA coverage targeting women 
aged 35-45 years old at five-year intervals is the most efficient and cost-saving 
strategy in reducing cervical cancer burden in the Philippines. Adding a vaccina-
tion program among 11-year old girls at a cost of Php 2,400 per vaccinated child is 
potentially cost-effective with the most favourable assumption that the vaccines 
provide lifelong immunity against HPV 16/18.
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objeCtives: Cancer therapy has been revolutionized by the introduction of tar-
geted therapy. Tremendous growth of its utilization was observed in Singapore over 
the past decade. Despite high treatment cost, most of the targeted therapies were 
not funded by Singapore’s unique health care financing system. Hence, this study 
aims to determine the trends of use of targeted therapy in National Cancer Centre 
Singapore from 2007-2011. In addition, treatment response and economic evalua-
tion of Gefitinib as a first line therapy for advanced NSCLC will be conducted to aid 
decision making. Methods: In this retrospective study, number of patients and 
annual consumption costs for each targeted therapy were determined. A total of 124 
chemo naive patients were identified to examine treatment response and resources 
used for Gefitinib. These were reviewed via electronic databases and medical reports. 
A Markov model was developed by using patient level data and utility values from 
literature. Cost utility analysis was performed from health care provider’s perspec-
tive with inclusion of direct medical costs (2012 Singapore dollars) and discount 
rate of 3%. Results: Dominant trends were observed in utilization of Trastuzumab 
(35%), Gefitinib (25%) and Bevacizumab (12%) over last 5 years. For Gefitinib, partial 
response and stable disease were 23.4% and 64.5% respectively. It resulted in a gain 
of 73.23 progression free days and 2.87 quality adjusted life year (QALY) with an 
additional cost of S$30,819.28. As a result, incremental cost-utility ratio (ICUR) of 
Gefitinib is S$10,749.86 per QALY and it was most sensitive to the cost of Gefitinib 
in one way sensitivity analysis. ConClusions: Top three drugs with high utiliza-
tion and consumption costs were Trastuzumab, Gefitinib and Bevacizumab. If the 
acceptable ICUR threshold in Singapore is 1 to 3 times of gross domestic product 
range, Gefitinib can be considered cost-effective compared to chemotherapy as first 
line treatment of NSCLC for local population.
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objeCtives: This study estimated health impact and cost-effectiveness of adding 
a quadrivalent HPV vaccination program for preadolescent girls to the existing 
cervical cancer screening program from the Thai payer perspective. Methods: A 
published transmission-dynamic model was adapted to Thailand setting. Both direct 
and indirect (herd immunity) benefits were captured by the model. Model inputs 
were obtained from literature, unpublished data and expert opinion. A proposed 
tender price of vaccine shown on recent news plus logistics, management and 
administration costs were used as vaccine-related costs to reflect the real situa-
tion of Thailand school-based HPV vaccination. Future costs and outcomes were 
discounted at 3%. Two vaccination strategies of combining cervical cancer screening 
with routine vaccination (11- to 12-year-old females) and with routine plus 5-year 
catch-up vaccination (13- to 24-year-old females) were compared to screening pro-
gram alone. Results: Adding HPV vaccination to the screening program provided 
both short- and long-term health benefits. Compared with current screening prac-
tice over 100 years, routine vaccination reduced cumulative incidence of cervical 
